George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGeiger Counter Regulatory News (GCL)

Share Price Information for Geiger Counter (GCL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.00
Bid: 52.00
Ask: 54.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.846%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 53.50
GCL Live PriceLast checked at -
Geiger Counter is an Investment Trust

To deliver attractive returns to shareholders principally in the form of capital growth, through investment in companies involved in the exploration, development and production of uranium to supply the nuclear power industry.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GCL Monthly Fact Sheet January 2024

23 Feb 2024 09:30

RNS Number : 2712E
Geiger Counter Ltd
23 February 2024

Geiger Counter Limited Plc

Monthly Investor Report - January

The full monthly factsheet is now available on the Company's website and a summary can be found below.

NCIM - Geiger Counter Ltd - Fund Page for Geiger Counter Ltd

Enquiries:

?

For the Investment Manager

CQS (UK) LLP

Craig Cleland

0207 201 5368

?

For the Company Secretary and Administrator

BNP Paribas S.A., Jersey Branch

Dean Plowman/Ann-Marie Pereira

01534 813 967/ 01534 709198

-----------------------------------------------------------------------

Fund Description

The objective of the Geiger Counter Fund is to provide investors with the potential for capital growth through investment primarily in the securities of companies involved in the exploration, development and production of energy, predominantly within the uranium industry. Up to 30% of the value of the Company's investment portfolio may be invested in other resource-related companies from outside the energy sector.

Portfolio Managers

Keith Watson and Robert Crayfourd

Key Advantages for the Investor

· Access to mining assets in the uranium sector

· May benefit from embedded subscription share

· Low correlation to major asset classes

Key Fund Facts1

Total Gross Assets

£116.7m

Reference Currency

GBP

Ordinary Shares:

Net Asset Value

78.38p

Mid-Market Price

62.00p

Net gearing4

13.50%

Discount

(20.90%)

Ordinary Share and NAV Performance2

One Month

Three Months

One Year

Three Years

Five Years

(%)

(%)

(%)

(%)

(%)

NAV

16.86

20.88

48.08

222.02

322.99

Share Price

14.81

28.50

32.62

141.25

217.95

Commentary3

The Fund's NAV gained 16.9% in January, ahead of the Solactive Uranium Pure Play index, which gained 10.5% in sterling terms, and the uranium price closed the month up 9.3% at $100/lb. The Fund's share price lagged the NAV.

The world's largest Uranium producer, Kazatomprom, reduced its production guidance for 2024 by 14% to 56.6M lbs, citing a shortage of sulphuric acid as the cause. Kazatomprom accounts for 24% of global production, but this impacts their joint venture partners equally for a total of ~40% of global production.4 This added to growing concerns from utilities on their ability to contract future volumes which should continue to support pricing.

The Fund remains weighted to producers with little to no hedging, to benefit from the anticipated pick up in contracting volumes at better terms than prior contracting levels, such as those seen with Cameco. Cameco and Kazatomprom are still buying material on the spot market, partly as utilities are maximising their contract flexibility to take larger volumes at lower prices given the fixed price components to those contracts. We remain underweight Cameco, relative to the Solactive Uranium Pure Play Index.

Following the US Senate vote to ban imports of Russian nuclear material, reports suggest it is increasingly likely to be voted through the House of Representatives in the coming weeks. Russia has already warned, via the state-owned uranium trader Tenex, that it could pre-emptively act to ban trade of uranium and associated services to the US. This continues to focus Western utility fuel buyers on the requirement to secure material and further encourages the trend to increase contracting with Western-friendly suppliers, where the Fund is positioned.

Whilst Russia is only 7% of primary uranium mined, they do have meaningful joint ventures with Kazatomprom and therefore influence a much larger share of the market than this figure implies. Importantly, they control a large proportion of global enrichment market, over 40%, which presents fuel supply risks for Western reactors should access be cut. In 2022 the US sourced 12% of its uranium and 24% of its enrichment from Russia.5

The Company announced on 8 February 2024 that it is considering applying for admission of the Company's ordinary shares to the Specialist Fund Segment of the London Stock Exchange as a means of broadening the appeal of the Company to a wider range of shareholders.

Gross Leverage

(%)

Commitment Leverage

(%)

Geiger Counter Ltd

114

114

CQS (UK) LLP

4th Floor, One Strand, London WC2N 5HR, United Kingdom

T: +44 (0) 20 7201 6900 | F: +44 (0) 20 7201 1200

CQS (US), LLC

152 West 57th Street, 40th Floor, New York, NY 10019, US

T: +1 212 259 2900 | F: +1 212 259 2699

CQS (Hong Kong) Limited

3305 AIA Tower, 183 Electric Road, North Point, Hong Kong, China

T: +852 3920 8600 | F: +852 2521 3189

Tavistock Communications

18 St. Swithin's Lane, London EC4N 8AD

T: +44 20 7920 3150 | geigercounter@tavistock.co.uk

Sources: 1R&H Fund Services (Jersey) Limited, as at the last business day of the month indicated at the top of this report. 2R&H Fund Services Limited/DataStream, as at the last business day of the month indicated at the top of this report, total return performance net of fees and expenses based on bid prices. These include historic returns and past performance is not a reliable indicator of future results. The value of investments can go down as well as up. Please read the important legal notice at the end of this document. 3Market data sourced from Bloomberg unless otherwise stated. The Fund may since have exited some or all of the positions detailed in the commentary.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DOCFIFLAFIIVFIS
Date   Source Headline
26th Apr 20242:15 pmRNSGCL MONTHLY FACT SHEET MARCH 2024
26th Apr 202412:15 pmRNSNet Asset Value(s)
26th Apr 202412:00 pmRNSShare Buyback
25th Apr 20242:45 pmRNSNet Asset Value(s)
25th Apr 20242:00 pmRNSShare Buyback
24th Apr 20242:40 pmRNSNet Asset Value(s)
24th Apr 20241:30 pmRNSShare Buyback
23rd Apr 20243:30 pmRNSNet Asset Value(s)
23rd Apr 20241:45 pmRNSShare Buyback
22nd Apr 20243:35 pmRNSNet Asset Value(s)
22nd Apr 20241:30 pmRNSShare Buyback
19th Apr 20242:35 pmRNSNet Asset Value(s)
18th Apr 20241:35 pmRNSNet Asset Value(s)
17th Apr 202412:20 pmRNSNet Asset Value(s)
16th Apr 20245:20 pmRNSNet Asset Value(s)
15th Apr 202412:50 pmRNSNet Asset Value(s)
12th Apr 20241:35 pmRNSNet Asset Value(s)
11th Apr 20241:15 pmRNSNet Asset Value(s)
10th Apr 20243:40 pmRNSNet Asset Value(s)
9th Apr 20241:25 pmRNSNet Asset Value(s)
8th Apr 20241:10 pmRNSNet Asset Value(s)
5th Apr 20242:05 pmRNSNet Asset Value(s)
4th Apr 20241:10 pmRNSNet Asset Value(s)
3rd Apr 20242:40 pmRNSNet Asset Value(s)
3rd Apr 20249:00 amRNSInvestment Manager Acquisition
2nd Apr 20243:50 pmRNSNet Asset Value(s)
28th Mar 20241:50 pmRNSNet Asset Value(s)
27th Mar 20241:00 pmRNSNet Asset Value(s)
27th Mar 20249:33 amRNSNotification to Shareholders - Subscription Rights
26th Mar 20242:55 pmRNSNet Asset Value(s)
25th Mar 20241:00 pmRNSNet Asset Value(s)
22nd Mar 20244:45 pmRNSPotential listing on the London Stock Exchange
22nd Mar 20241:15 pmRNSNet Asset Value(s)
21st Mar 20241:25 pmRNSNet Asset Value(s)
20th Mar 20242:30 pmRNSNet Asset Value(s)
19th Mar 20244:45 pmRNSNet Asset Value(s)
18th Mar 20241:45 pmRNSNet Asset Value(s)
15th Mar 202411:35 amRNSNet Asset Value(s)
14th Mar 202412:45 pmRNSNet Asset Value(s)
13th Mar 20242:15 pmRNSNet Asset Value(s)
12th Mar 20245:00 pmRNSAGM Statement - Results of AGM 2024
12th Mar 20241:00 pmRNSNet Asset Value(s)
11th Mar 20241:35 pmRNSNet Asset Value(s)
8th Mar 20242:45 pmRNSNet Asset Value(s)
7th Mar 20242:45 pmRNSNet Asset Value(s)
6th Mar 20241:40 pmRNSNet Asset Value(s)
5th Mar 20242:30 pmRNSNet Asset Value(s)
4th Mar 20241:30 pmRNSNet Asset Value(s)
1st Mar 20243:15 pmRNSNet Asset Value(s)
29th Feb 20241:45 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.